Pfizer and Moderna stocks tumble over anticipated low COVID-19 vaccination rate

  • 📰 dcexaminer
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 94%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Pfizer, BioNTech, and Moderna stock prices fell precipitously on Monday as a result of anticipated low uptake rates for the updated COVID-19 vaccines.

Pfizer CFO David Denton said at a press conference on Monday that he anticipates 24% of the U.S. population, or 82 million people, will receive the updated COVID-19 vaccines that received approval from the Food and Drug Administration last week.As of May, only 17% of the nation had received the bivalent booster vaccination against COVID-19, according to data from the Centers for Disease Control and Prevention.

Pfizer and BioNTech announced on Tuesday of last week at a CDC advisory meeting that they would be charging approximately $120 for their mRNA COVID-19 vaccines, while Moderna would be charging closer to $130. The Biden administration announced in July that it would begin commercializing the COVID-19 preparedness strategy, only relying upon government-purchased vaccines for those without insurance or with insurance that would not cover the updated shot.

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 6. in RU
 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

Stocks making the biggest moves midday: Marathon Petroleum, Tesla, Moderna and moreThese are the stocks posting the largest moves in midday trading.
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »